EntryPoint Capital LLC Decreases Position in Haemonetics Co. (NYSE:HAE)

EntryPoint Capital LLC trimmed its stake in Haemonetics Co. (NYSE:HAE) by 58.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 2,854 shares of the medical instruments supplier’s stock after selling 3,943 shares during the period. EntryPoint Capital LLC’s holdings in Haemonetics were worth $223,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Wellington Management Group LLP grew its holdings in Haemonetics by 9.5% during the 3rd quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock valued at $337,722,000 after purchasing an additional 363,702 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Haemonetics by 14.9% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier’s stock valued at $98,716,000 after buying an additional 164,111 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Haemonetics by 1.8% during the third quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier’s stock valued at $95,986,000 after buying an additional 21,547 shares during the last quarter. Boston Trust Walden Corp raised its holdings in shares of Haemonetics by 13.1% in the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock worth $71,500,000 after buying an additional 106,114 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Haemonetics by 0.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 801,049 shares of the medical instruments supplier’s stock valued at $62,802,000 after acquiring an additional 5,668 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

HAE has been the topic of a number of recent analyst reports. Raymond James reiterated a “strong-buy” rating and issued a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a report on Friday, December 6th. They set an “overweight” rating and a $116.00 price objective for the company. Barrington Research dropped their target price on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. Finally, Needham & Company LLC reduced their price objective on Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $101.22.

Haemonetics Trading Down 1.8 %

Shares of NYSE:HAE opened at $63.03 on Friday. The company has a market capitalization of $3.17 billion, a PE ratio of 24.81, a P/E/G ratio of 1.11 and a beta of 0.43. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 12-month low of $58.80 and a 12-month high of $97.97. The business’s fifty day simple moving average is $66.05 and its 200-day simple moving average is $74.68.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, equities research analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.